This week, we’ll be featuring three researchers discussing findings presented at the 2020 Gastrointestinal Cancers Symposium:

Dr. Scott Kopetz, of The University of Texas MD Anderson Cancer Center, discusses quality-of-life results from the BEACON CRC trial in BRAF V600E–mutated colorectal cancer. Dr. Brian Wolpin, of Dana-Farber Cancer Institute, talks about the efficacy of a blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal cancers. Dr. Zev Wainberg, of UCLA Medical Center, discusses a subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembrolizumab in patients with PD-L1–positive disease.

Coverage of stories discussed this week on ascopost.com:

2020 GI Cancers Symposium: Patient-Reported Outcomes From IMbrave150, BEACON CRC

2020 GI Cancers Symposium: Detecting GI Tumors Using a Cell-Free DNA Test